SecBot SecBot
DEFA14A ·Filed Nov 12, 2026

SKYE

Skye Bioscience, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4d 18h ago SEC0001628280-26-073123
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for post-trial motions or appeal by plaintiff; the Redx acquisition proxy vote and Nasdaq listing status are the next key catalysts for this micro-cap.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.08
T+0 close · Nov 12, 2026 · via day close
Latest settled
+0.93%
T+1 · $1.09
Vs SPY
+1.29%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $1.08entry
  2. T+1 · 4d ago +0.93%α +1.29% · $1.09
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Skye Bioscience filed a DEFA14A disclosing a unanimous jury verdict in its favor in a former employee's whistleblower retaliation lawsuit, and reminding shareholders of the proposed acquisition of Redx Pharma. The legal win removes a material contingent liability, but the company's $4M market cap and ongoing activist context keep the focus on the Redx deal and Nasdaq listing risk.

Key Financial Metrics

Vote
merger approval

Key Facts

  • On November 10, 2026, a jury returned a unanimous verdict in favor of Skye on all claims in the Wendy Cunning whistleblower lawsuit.
  • The lawsuit alleged SOX whistleblower violations and California retaliation, seeking unspecified economic and non-economic losses plus attorneys' fees.
  • The plaintiff may file post-trial motions and appeal; the company cannot predict the outcome.
  • The filing also references the proposed acquisition of Redx Pharma Limited, for which a preliminary proxy statement has been filed.
  • Skye's market cap is $4M; activist 5AM Partners VII holds 25.7% and has been selling shares.
  • The company faces Nasdaq listing risk, noted in forward-looking statements.

Financial Impact

Lawsuit sought unspecified damages; verdict eliminates potential liability but no financial figure stated.

legal liability

Risk Factors

  • Plaintiff may file post-trial motions or appeal the verdict.
  • Redx acquisition may not close or may be delayed; stockholder approval and regulatory conditions remain.
  • Nasdaq listing risk is explicitly noted in forward-looking statements.
  • Activist 5AM Partners has been reducing its 25.7% stake, signaling reduced conviction.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001628280-26-073123
Document: 0001628280-26-073123-index-headers.html0001628280-26-073123
Document: 0001628280-26-073123-index.html0001628280-26-073123
Document: 0001628280-26-073123.txt0001628280-26-073123

Track record

16 reports on SKYE

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago DEFA14A Neutral 3/10 Viewing Entry $1.08 Now $1.07 −1.39% settles Dec 11
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  3. Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
  4. Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
  5. Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
  6. Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
  7. Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
  8. Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
  9. Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
  10. Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026